Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
about
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107Non-Clear Cell Renal Cell Carcinoma: Current Management and Best PracticeDifferential responses of MET activations to MET kinase inhibitor and neutralizing antibody
P2860
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Biomarker-Based Phase II Trial ...... d Papillary Renal Cell Cancer.
@ast
Biomarker-Based Phase II Trial ...... d Papillary Renal Cell Cancer.
@en
type
label
Biomarker-Based Phase II Trial ...... d Papillary Renal Cell Cancer.
@ast
Biomarker-Based Phase II Trial ...... d Papillary Renal Cell Cancer.
@en
prefLabel
Biomarker-Based Phase II Trial ...... d Papillary Renal Cell Cancer.
@ast
Biomarker-Based Phase II Trial ...... d Papillary Renal Cell Cancer.
@en
P2093
P356
P1476
Biomarker-Based Phase II Trial ...... d Papillary Renal Cell Cancer.
@en
P2093
Amir A Handzel
Daniel Y C Heng
Edwin A Clark
Elizabeth Plimack
Eric Jonasch
Hendrik-Tobias Arkenau
Humphrey Gardner
Laurence Albiges
Melanie M Frigault
Shethah Morgan
P304
JCO2017722967
P356
10.1200/JCO.2017.72.2967
P407
P577
2017-06-23T00:00:00Z